Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype?

Full text
Author(s):
Ramos, Marcus F. K. P. [1] ; Pereira, Marina A. [2] ; Amorim, Larissa C. [3] ; de Mello, Evandro S. [2] ; Faraj, Sheila F. [2] ; Ribeiro Jr, Ulysses ; Hoff, Paulo M. G. [3] ; Cecconello, Ivan [4] ; de Castria, Tiago B. [5, 3]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Dept Gastroenterol, Fac Med, Hosp Clin HCFMUSP, Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Dept Pathol, Sao Paulo, SP - Brazil
[3] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Dept Radiol & Oncol, Sao Paulo, SP - Brazil
[4] Ribeiro Jr, Jr., Ulysses, Univ Sao Paulo, Dept Gastroenterol, Fac Med, Hosp Clin HCFMUSP, Sao Paulo, SP - Brazil
[5] Sirio Libanes Hosp, Sao Paulo, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: JOURNAL OF SURGICAL ONCOLOGY; v. 121, n. 5 DEC 2019.
Web of Science Citations: 3
Abstract

Background Gastric cancer (GC) has been defined in distinct molecular subtypes with different therapeutic implications. However, its clinical significance and prognosis regarding standard chemotherapy (CMT) remains unclear. This study aimed to analyze the impact of perioperative or adjuvant treatment among subtypes of GC. Methods We retrospectively evaluated all stage II/III patients with GC who underwent a curative gastrectomy. Based on immunohistochemistry and in situ hybridization techniques, GC was classified into five subtypes: Epstein-Barr virus (EBV) positive, microsatellite instability (MSI), e-cadherin aberrant, p53-aberrant, and p53-normal. Results Among the 178 CG included, 111 patients received CMT and 67 were treated with surgery alone. Survival analysis showed that p53-aberrant GC treated with CMT had better disease-free survival (DFS) compared with surgery alone (P = .001).There was no significant difference in DFS between patients who received CMT and those with surgery alone for EBV, MSI, E-cadherin, and p53-normal GC. An improvement in overall survival was observed only for E-cadherin (P = .001) and p53-aberrant (P < .001) patients who received CMT. Conclusions CMT showed different impact on the survival of CG according to the molecular subtype. No survival benefit was observed for EBV and MSI groups who received CMT. GC with p53-aberrant had a significant benefit in survival with standard therapy. (AU)

FAPESP's process: 16/25524-0 - Characterization of Helicobacter pylori infection, Epstein-Barr virus and gene-protein expression profile in gastric adenocarcinomas
Grantee:Ulysses Ribeiro Júnior
Support Opportunities: Regular Research Grants